CODX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Co-Diagnostics Inc. is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces significant challenges, including a recent downgrade, delisting risks, and poor financial performance. While the company has announced expansion efforts in South Asia, these are not sufficient to offset the negative catalysts and financial instability.
The technical indicators show a bearish trend with moving averages (SMA_200 > SMA_20 > SMA_5) and a neutral RSI (25.337). The MACD is slightly positive (0.0645), but the overall trend remains weak. Key support is at 1.971, and resistance is at 3.521, indicating limited upside potential.
The company has announced an expansion into South Asia, targeting a $13 billion molecular diagnostics market. It has also partnered with CoSara Diagnostics to enhance commercialization potential.
Analysts have downgraded the stock to Hold from Buy.
In Q3 2025, the company's revenue dropped to $145,380 (-77.32% YoY), net income fell to -$5,886,823 (-39.29% YoY), and EPS declined to -4.66 (-51.15% YoY). Gross margin improved to -102 but remains negative, indicating severe financial struggles.
Analysts have downgraded the stock to Hold from Buy, citing delisting risks and challenges in raising capital without a major exchange listing. While the company's technology and products have potential, these factors are overshadowed by its financial and operational challenges.
